Comprehensive genomic profiling (CGP) of ovarian clear cell carcinomas (OCCC) identifies clinically relevant genomic alterations (CRGA) and targeted therapy options

• MTOR pathway genes are often mutated in ovarian clear cell carcinomas (OCCC). • 11.2% of OCCC have targetable alterations only in the mTOR pathway. • MTOR pathway mutations in OCCC can underlie robust, lasting responses to everolimus.

Detalles Bibliográficos
Autores principales: Elvin, Julia A., Chura, Justin, Gay, Laurie M., Markman, Maurie
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2017
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5357688/
https://www.ncbi.nlm.nih.gov/pubmed/28349114
http://dx.doi.org/10.1016/j.gore.2017.02.007
_version_ 1782516084567441408
author Elvin, Julia A.
Chura, Justin
Gay, Laurie M.
Markman, Maurie
author_facet Elvin, Julia A.
Chura, Justin
Gay, Laurie M.
Markman, Maurie
author_sort Elvin, Julia A.
collection PubMed
description • MTOR pathway genes are often mutated in ovarian clear cell carcinomas (OCCC). • 11.2% of OCCC have targetable alterations only in the mTOR pathway. • MTOR pathway mutations in OCCC can underlie robust, lasting responses to everolimus.
format Online
Article
Text
id pubmed-5357688
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-53576882017-03-27 Comprehensive genomic profiling (CGP) of ovarian clear cell carcinomas (OCCC) identifies clinically relevant genomic alterations (CRGA) and targeted therapy options Elvin, Julia A. Chura, Justin Gay, Laurie M. Markman, Maurie Gynecol Oncol Rep Case Report • MTOR pathway genes are often mutated in ovarian clear cell carcinomas (OCCC). • 11.2% of OCCC have targetable alterations only in the mTOR pathway. • MTOR pathway mutations in OCCC can underlie robust, lasting responses to everolimus. Elsevier 2017-03-01 /pmc/articles/PMC5357688/ /pubmed/28349114 http://dx.doi.org/10.1016/j.gore.2017.02.007 Text en © 2017 The Authors http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Case Report
Elvin, Julia A.
Chura, Justin
Gay, Laurie M.
Markman, Maurie
Comprehensive genomic profiling (CGP) of ovarian clear cell carcinomas (OCCC) identifies clinically relevant genomic alterations (CRGA) and targeted therapy options
title Comprehensive genomic profiling (CGP) of ovarian clear cell carcinomas (OCCC) identifies clinically relevant genomic alterations (CRGA) and targeted therapy options
title_full Comprehensive genomic profiling (CGP) of ovarian clear cell carcinomas (OCCC) identifies clinically relevant genomic alterations (CRGA) and targeted therapy options
title_fullStr Comprehensive genomic profiling (CGP) of ovarian clear cell carcinomas (OCCC) identifies clinically relevant genomic alterations (CRGA) and targeted therapy options
title_full_unstemmed Comprehensive genomic profiling (CGP) of ovarian clear cell carcinomas (OCCC) identifies clinically relevant genomic alterations (CRGA) and targeted therapy options
title_short Comprehensive genomic profiling (CGP) of ovarian clear cell carcinomas (OCCC) identifies clinically relevant genomic alterations (CRGA) and targeted therapy options
title_sort comprehensive genomic profiling (cgp) of ovarian clear cell carcinomas (occc) identifies clinically relevant genomic alterations (crga) and targeted therapy options
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5357688/
https://www.ncbi.nlm.nih.gov/pubmed/28349114
http://dx.doi.org/10.1016/j.gore.2017.02.007
work_keys_str_mv AT elvinjuliaa comprehensivegenomicprofilingcgpofovarianclearcellcarcinomasocccidentifiesclinicallyrelevantgenomicalterationscrgaandtargetedtherapyoptions
AT churajustin comprehensivegenomicprofilingcgpofovarianclearcellcarcinomasocccidentifiesclinicallyrelevantgenomicalterationscrgaandtargetedtherapyoptions
AT gaylauriem comprehensivegenomicprofilingcgpofovarianclearcellcarcinomasocccidentifiesclinicallyrelevantgenomicalterationscrgaandtargetedtherapyoptions
AT markmanmaurie comprehensivegenomicprofilingcgpofovarianclearcellcarcinomasocccidentifiesclinicallyrelevantgenomicalterationscrgaandtargetedtherapyoptions

Ejemplares similares